Charcot neuro-osteoarthropathy is one of the most consequential — and most frequently missed — complications of diabetes affecting the foot. It is a progressive condition in which bones weaken, fracture, and dislocate in a foot that has lost protective sensation, often without the patient feeling significant pain. Left unrecognized, the once-stable architecture of the foot can collapse within weeks, producing a rigid, deformed “rocker-bottom” foot that is highly prone to ulceration, infection, and ultimately amputation. Because early Charcot can look deceptively benign, understanding how it presents and how it is managed is critical for patients, caregivers, and clinicians alike.
Why Charcot Foot Is So Easily Missed
The earliest sign of active Charcot is often nothing more than a warm, red, swollen foot. This unremarkable presentation is precisely what makes it dangerous. A systematic review of Charcot misdiagnosis found that the condition is frequently mistaken for cellulitis, deep vein thrombosis, gout, osteomyelitis, or a simple sprain (Schmidt et al., 2022). Estimates suggest that up to a quarter of acute cases are initially misidentified, and diagnostic delays of several weeks to months are common — delays that allow irreversible bony destruction to occur before treatment begins.
A defining feature of Charcot is that it develops in a foot affected by peripheral neuropathy. Because protective pain sensation is diminished or absent, patients continue walking on an actively fracturing foot, accelerating the damage. Any person with diabetes, neuropathy, and a unilaterally warm, swollen foot should be considered to have active Charcot until proven otherwise.
Establishing the Diagnosis
Clinical assessment and skin temperature
The 2023 International Working Group on the Diabetic Foot (IWGDF) guideline — the first international, evidence-based guideline dedicated to Charcot — emphasizes that diagnosis begins clinically (Wukich et al., 2024). A hallmark finding is a temperature difference of greater than 2°C between the affected foot and the opposite foot, readily measured with an inexpensive infrared skin thermometer. Confirming the presence of neuropathy through monofilament and vibration testing is also a prerequisite, since Charcot does not occur in a foot with intact sensation.
Imaging
Plain X-rays of both feet should be obtained for comparison, but the IWGDF cautions that early Charcot can produce normal-appearing radiographs even when significant disease is present. When clinical suspicion is high and X-rays are unrevealing, MRI is the imaging test of choice. Bone marrow edema is a hallmark of the active phase and is visible on MRI well before bony changes appear on plain film, making advanced imaging valuable for confirming the diagnosis and avoiding costly delay.
Treatment: Offloading and Immobilization
The cornerstone of managing active Charcot is prompt and sustained offloading to protect the foot while the acute inflammatory process resolves. A total contact cast — or an equivalent nonremovable knee-high device — is the recommended first-line treatment, immobilizing the foot and limiting the mechanical forces that drive further collapse. Treatment is typically prolonged, often lasting several months, and requires strict adherence because the absence of pain gives patients little natural incentive to rest the limb.
Knowing when to progress
Deciding when a foot has cooled enough to transition out of a cast has historically been challenging. A 2023 systematic review examined contralateral skin temperature monitoring during Charcot immobilization and found that a sustained temperature difference of less than 2°C between the two feet is widely used as the threshold for safely stepping down to protective footwear (Jones et al., 2023). Progressing too early risks reactivating the disease, so clinicians generally require the temperature to remain below this threshold across several visits before advancing.
The role of surgery
Most cases of active Charcot are managed without surgery. However, when severe deformity, instability, or recurrent ulceration develops, reconstructive surgery may be considered to restore a stable, plantigrade foot that can be safely fitted with footwear (Wukich et al., 2024). These are complex procedures reserved for selected patients, and strict non-weight-bearing after surgery is essential to protect the reconstruction.
Key Takeaways
Charcot neuro-osteoarthropathy is a medical urgency in which early recognition changes outcomes dramatically. The combination of a warm, swollen foot in a person with diabetic neuropathy — particularly with a greater than 2°C temperature difference between feet — should prompt immediate evaluation and, when suspicion is high, advanced imaging. Timely, sustained offloading in a total contact cast remains the foundation of treatment, with skin temperature guiding the safe transition back to weight-bearing. Because the condition is so often mistaken for more common problems, awareness among patients and clinicians remains the single most powerful tool for preventing permanent deformity and preserving the limb.
References
Wukich DK, Raspovic KM, Hobizal KB, et al. Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023). Diabetes/Metabolism Research and Reviews. 2024.
Jones PJ, Davies MJ, Webb D, et al. Contralateral foot temperature monitoring during Charcot immobilisation: A systematic review. Diabetes/Metabolism Research and Reviews. 2023.
Schmidt BM, Holmes CM, et al. A systematic review of Charcot neuroarthropathy misdiagnosis. Journal of Diabetes and Its Complications / PMC. 2022.
Rosenbaum AJ, DiPreta JA. Diabetic Foot. Part 2: Charcot Neuroarthropathy. Medical Clinics of North America. 2020.
Petrova NL, Edmonds ME. Charcot Foot: An Update on Diagnosis, Treatment, and Areas of Uncertainty. Current Diabetes Reports / peer-reviewed literature. 2024.
Comments
